2023 Chinese guideline for lipid management
Jian-Jun Li,Shui-Ping Zhao,Dong Zhao,Guo-Ping Lu,Dao-Quan Peng,Jing Liu,Zhen-Yue Chen,Yuan-Lin Guo,Na-Qiong Wu,Sheng-Kai Yan,Zeng-Wu Wang,Run-Lin Gao,Hong Chen,Zhenyue Chen,Xiang Cheng,Yundai Chen,Zhenyue Chen,Yugang Dong,Kefei Dou,Runlin Gao,Dongfeng Gu,Junbo Ge,Wei Gao,Yifang Guo,Yuanlin Guo,Runlin Gao,Yuanlin Guo,Ying Gao,Yong Huo,Suling Han,Dayi Hu,Weiping Jia,Linong Ji,Meilin Liu,Jianjun Li,Guoping Lu,Yong Li,Jing Li,Xiaoying Li,Guangwei Li,Yuhua Liao,Guoping Lu,Jing Liu,Jianjun Li,Chun Liang,Changsheng Ma,Yitong Ma,Liyuan Ma,Guang Ning,Daoquan Peng,Daoquan Peng,Yihong Sun,Xubo Shi,Yida Tang,Zengwu Wang,Zengwu Wang,Naqiong Wu,Yangfeng Wu,Zengwu Wang,Naqiong Wu,Chengbin Wang,Yongjun Wang,Wei Xiang,Shengkai Yan,Xiaowei Yan,Shengkai Yan,Zuyi Yuan,Bo Yu,Ping Ye,Dalong Zhu,Yun Zhang,Jiajun Zhao,Dong Zhao,Shuiping Zhao,Dajin Zou,Jian Zhang,Ruiyan Zhang,Zhou Zhou,Wenhua Zhao,Ye Zhu,Zhiming Zhu,Zhengpei Zeng,Siyan Zhan,Dong Zhao,Shuiping Zhao
DOI: https://doi.org/10.3389/fphar.2023.1190934
IF: 5.6
2023-08-30
Frontiers in Pharmacology
Abstract:Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the "Guidelines for the prevention and treatment of dyslipidemia" were adapted into the "Chinese guideline for Lipid Management" (henceforth referred to as the new guidelines) by an Experts' committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with cardiovascular disease (CVD) risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.
pharmacology & pharmacy